
- /
- Supported exchanges
- / STU
- / 41ON.STU
Outlook Therapeutics Inc (41ON STU) stock market data APIs
Outlook Therapeutics Inc Financial Data Overview
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Outlook Therapeutics Inc data using free add-ons & libraries
Get Outlook Therapeutics Inc Fundamental Data
Outlook Therapeutics Inc Fundamental data includes:
- Net Revenue: 5 854 K
- EBITDA: -82 872 496
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-02-12
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Outlook Therapeutics Inc News

Outlook Therapeutics® to Present at the BTIG Virtual Biotechnology Conference 2023
Outlook Therapeutics, Inc. Live webcast fireside chat on Monday, August 7th at 1:00 PM ET ISELIN, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceuti...


When Will Outlook Therapeutics, Inc. (NASDAQ:OTLK) Turn A Profit?
Outlook Therapeutics, Inc. (NASDAQ:OTLK) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Outlook Therapeutics, Inc., a late clinical-s...

Why Shares of Outlook Therapeutics Rose Tuesday
Shares of Outlook Therapeutics (NASDAQ: OTLK) were up 6.3% early Tuesday afternoon after rising as much as 16% earlier in the day. The clinical-stage biotech is awaiting a key prescription drug user f...

Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2023 and Provides Corporate Update
Outlook Therapeutics, Inc. Upcoming Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023 for ONS-5010, an investigational ophthalmic formulation of bevacizumab for the treatment of wet...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.